Skip to main content


Figure 2 | BMC Health Services Research

Figure 2

From: Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study

Figure 2

Increase in charges from 1-year preindex to 1-year postindex periods for treatment-related comorbid events, by treatment duration. Data on four mutually exclusive groups are presented: those who discontinued PEG-IFN-alfa/ribavirin between weeks 1–12, weeks 13–24, weeks 25–47, and after week 47. For all groups, annual charges are shown.

Back to article page